In recent years, oncology has undergone a transformation: it is not enough to know where a tumor originated; today it matters What drives him at the molecular level. The treatments tumor-agnostics They target genetic alterations shared by tumors in different organs, opening new therapeutic options for patients who previously had none. In this post, we explain in clear language what this approach means, what the key biomarkers are, and when a test is indicated. NGS It can be a determining factor in clinical practice.
(And why more and more doctors are requesting genomic studies like NGS)
For many years, cancer was classified and treated primarily according to the part of the body where it appeared: breast cancer, lung cancer, colon cancer, prostate cancer, etc. Each diagnosis followed very different paths, even when some tumors shared very similar biological characteristics.
But in recent years something changed forever: We are beginning to understand that cancer is not defined solely by the organ where it starts, but by the genetic alterations that drive it..
This is where a new concept emerges that is transforming medicine: the tumor-agnostic cancer.
What does “tumor agnostic” really mean?
A tumor-agnostic cancer is one that It is not classified by location., but by a specific molecular alteration that can be found in different types of tumors.
This means that Two patients with cancer in completely different organs can receive the same treatment, provided they share the same mutation or biomarker.
Examples of these alterations include:
- MSI-H (high microsatellite instability)
- High TMB (high mutational burden)
- Mergers in NTRK
- Mutation BRAF V600E
- Alterations in RET o KRAS G12C
When a tumor exhibits one of these signs, it may respond to targeted therapies regardless of where it started.
Why is this new way of classifying cancer so important?
Because for the first time, we can:
1. To classify cancer with much greater accuracy
We no longer just see which organ is affected, but What is driving the tumor at a genetic level?.
2. Offer more personalized treatments
Targeted therapies can be more effective and cause fewer adverse effects when the treatment is tailored to the exact mutation of the tumor.
3. Identify options even when the tumor is rare or difficult to classify
For patients with metastatic cancer or cancer of uncertain primary origin, genomic studies can reveal options that previously seemed nonexistent.
4. Save critical time
A single NGS test can provide a complete map of the alterations, avoiding multiple isolated studies.
How can you tell if a cancer is “tumor agnostic”?
Through advanced genomic studies, especially next-generation sequencing (NGS) panels.
These tests analyze hundreds of cancer-related genes in a single sample, identifying:
- Mutations
- Gene fusions
- Actionable alterations
- Biomarkers such as MSI-H and TMB
This information allows us to determine if there is an approved therapy for that type of disorder, regardless of the organ affected.
Who benefits most from this type of study?
Although any cancer patient can benefit, cases where NGS is especially useful include:
- metastatic or advanced cancer
- Rare or uncommon tumors
- Cancer of unknown primary origin
- Patients who have already received several treatments without response
- Patients seeking targeted therapies or clinical trials
Zogen's role in this whole process
We know that requesting a genomic test can seem complicated for doctors and patients: paperwork, insurance authorization, sample shipment, response times…
But It doesn't have to be..
At Zogen we are a technological bridge between doctors, patients and leading international laboratories in genomic studies.
We take care of all the management: application, documentation, logistics, sending samples and support during the process.
In this way, the doctor's focus can remain on what is most important: patient health and treatment decisions.
📞 Do you want to know if you or your patient could benefit from an NGS test?
We offer free consultations to guide patients and doctors on which test is most appropriate in each case.
👉 Request personalized advice: +52 331720 0760
👉 Meet the specialists in our Medical Directory: zogen.mx/directory
📚 Scientific sources consulted
- Shah, N.M., & Meric-Bernstam, F. (2025). The present and future of precision oncology and tumor-agnostic therapeutic approaches. The Oncologist.
- Subbiah, V. (2024). The evolving landscape of tissue-agnostic therapies in cancer.
- Nguyen, K., et al. (2024). Histology-Agnostic Drug Development: An Updated Review. Cancers.
- Sledge, G.W., Jr., et al. (2025). Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals. Nature Communications.
